Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 72
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Med Sci Monit ; 28: e936495, 2022 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-35591768

RESUMEN

BACKGROUND The aim of this study was to determine the level of anti-hemagglutinin antibodies in the serum of recovered patients during the SARS-CoV-2 pandemic in the 2019/2020 epidemic season in Poland, and the course of COVID-19. MATERIAL AND METHODS The material for the study consisted of the sera of COVID-19 convalescents obtained from the following 9 Regional Blood Donation and Blood Supply Centers located in 8 voivodeships. The hemagglutination inhibition reaction assay (HAI) using 8 viral hemagglutination units was used to determine antibody levels, in accordance with WHO recommendations. RESULTS This research confirms that a patient's declared severity of the course of SARS-CoV-2 infection is influenced by the patient's age and concomitant diseases. There was no statistically significant correlation between the level of anti-hemagglutinin antibodies and the severity of the course of a SARS-CoV-2 infection. Based on the serological tests conducted, it can be unequivocally concluded that both vaccinated and influenza-infected patients had a response rate in line with the requirements of the European Commission and the Committee for Medicinal Products for Human Use hemagglutinin antibodies for 4 influenza virus antigens tested. CONCLUSIONS Patients who confirmed their antibody levels with the Commission of the European Communities and the Committee for Propriety Medicinal Products (CPMP) requirements had a mild COVID-19 course. The results of our research emphasize the role of anti-hemagglutinin antibodies in the course of SARS-CoV-2 infection. COVID-19 convalescents have a higher response rate against all 4 types of anti-hemagglutinin antibodies analyzed.


Asunto(s)
COVID-19 , Gripe Humana , Anticuerpos Antivirales , COVID-19/epidemiología , Hemaglutininas , Humanos , Pandemias , Polonia/epidemiología , SARS-CoV-2 , Estaciones del Año
2.
Med Sci Monit ; 28: e937953, 2022 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-36329623

RESUMEN

BACKGROUND Influenza can be the most dangerous for people in risk groups, for example for seniors, in whom it can lead to serious and life-threatening complications. The aim of this research was to analyze the activity of influenza viruses and influenza-like viruses in patients over 65 years of age in the 2019-2020 epidemic season in Poland. MATERIAL AND METHODS A total of 1269 samples collected from patients over 65 years of age with suspected influenza or other respiratory viruses in the 2019-2020 epidemic season (from October 1, 2019, to September 30, 2020) were analyzed. The test material was nose and throat swabs collected during the 2019-2020 epidemic season. Quantitative polymerase chain reaction was used to determine the influenza virus type and subtype for positive samples. RESULTS Among the confirmed infections with influenza viruses, cases due to influenza A were dominant, and the dominant subtype was influenza A subtype A/H1N1/pdm09. Infections with influenza-like viruses were also confirmed in the patients participating in the study, with the presence of genetic material of respiratory syncytial viruses confirmed most often. CONCLUSIONS Seasonal vaccinations can significantly reduce the number of cases and thus the risk of post-influenza complications and deaths among seniors. This is very important, especially now, due to the current epidemiological situation related to the ongoing SARS-CoV-2 respiratory virus pandemic.


Asunto(s)
COVID-19 , Subtipo H1N1 del Virus de la Influenza A , Gripe Humana , Virus , Humanos , Lactante , Gripe Humana/epidemiología , Estaciones del Año , Polonia/epidemiología , SARS-CoV-2
3.
Med Sci Monit ; 27: e929243, 2021 Jan 19.
Artículo en Inglés | MEDLINE | ID: mdl-33465057

RESUMEN

BACKGROUND Influenza is a viral disease causing many deaths each season. With aging, the human immune system becomes weaker, so people over the age of 65 years are at higher risk of complications after influenza infections. This population study, conducted in Poland, aimed to identify the subtypes of influenza virus infection and outcomes in individuals more than 65 years of age in the 2016/2017 to 2019/2020 epidemic seasons. MATERIAL AND METHODS The research materials were nose and throat swabs. Research was conducted in 16 Voivodship Sanitary and Epidemiological Stations and in the Department of Influenza Research, National Influenza Centre, NIPH-NIH. Methods of RNA isolation depended on the laboratory where the isolation was performed. In all laboratories, quantitative polymerase chain reaction (qRT-PCR) was used to determine the influenza virus type and subtype. RESULTS The analysis of the incidence of influenza among people over the age of 65 included the 2016/2017, 2017/2018, 2018/2019, and 2019/2020 influenza epidemic seasons. We analyzed the percentage of positive samples, the dynamics of epidemic seasons, and the percentage share of influenza viruses in the 65+ age group, according to the epidemic season and percentage of deaths. CONCLUSIONS This population study showed that, in Poland, between the 2016/2017 and 2019/2020 epidemic seasons, people who were more than 65 years of age were at higher risk of influenza virus infection and its complications. The findings support the importance of seasonal influenza vaccination in the population over age 65 years.


Asunto(s)
Evaluación Geriátrica/métodos , Gripe Humana/epidemiología , Distribución por Edad , Anciano , Epidemias/estadística & datos numéricos , Femenino , Humanos , Incidencia , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Masculino , Polonia/epidemiología , Medición de Riesgo
4.
Med Sci Monit ; 27: e929572, 2021 May 17.
Artículo en Inglés | MEDLINE | ID: mdl-33994536

RESUMEN

BACKGROUND Obesity is associated with susceptibility to severe influenza infection and several disturbances of the immune response to the influenza vaccine. However, the effect of obesity on the immunogenicity of the influenza vaccine is not fully understood. Our objective here was to assess the immunogenicity of the split, inactivated quadrivalent influenza vaccine (QIV) in Polish adults with obesity. MATERIAL AND METHODS Fifty-three subjects with obesity aged 21-69 years were vaccinated with the QIV in 2017/2018 season. Antibody titers against the 4 vaccine strains were measured using the hemagglutination inhibition (HI) assay. The mean fold antibody increase (MFI), seroprotection rate (protection rate, PR), and seroconversion rate (response rate, RR) were calculated to assess vaccine immunogenicity. RESULTS The vaccine elicited a significant increase in the anti-HI titers against the QIV antigens. The MFI, PR, and RR for the QIV antigens also reached the required age-specific values, indicating the QIV meets current immunogenicity criteria. Individuals with class I and class II/III obesity had similar anti-HI titers, MFI, PR, and RR to each of the vaccine strains. Adults aged <60 years had similar anti-HI titers, MFI, PR, and RR to the QIV strains to those aged ≥60 years. CONCLUSIONS Our results indicate that the split virion, inactivated QIV is immunogenic in adults with obesity regardless of their degree of obesity and age (ie, <60 and ≥60 years).


Asunto(s)
Inmunogenicidad Vacunal/inmunología , Vacunas contra la Influenza/inmunología , Gripe Humana/inmunología , Obesidad/inmunología , Adulto , Anciano , Anticuerpos Antivirales/inmunología , Femenino , Humanos , Gripe Humana/prevención & control , Gripe Humana/virología , Masculino , Persona de Mediana Edad , Obesidad/virología , Estaciones del Año , Seroconversión/fisiología , Adulto Joven
5.
Med Sci Monit ; 27: e934862, 2021 12 12.
Artículo en Inglés | MEDLINE | ID: mdl-34897266

RESUMEN

BACKGROUND This population study aimed to investigate influenza and influenza-like respiratory virus infections in children during the 2019/20 influenza season and the coronavirus disease 2019 (COVID-19) pandemic in Poland. MATERIAL AND METHODS This study analyzed data from the National Influenza Centre, the Department of Influenza Research at the National Institute of Public Health, and 16 Voivodeship Sanitary and Epidemiological Stations in Poland. Nose and throat swabs were obtained from children during the 2019/20 influenza season and the COVID-19 pandemic. Viral RNA detection was performed using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to diagnose influenza virus infection and viral subtypes. RESULTS In the analyzed group, both cases of influenza A and B and infections with influenza-like viruses were confirmed. Among all cases caused by influenza viruses, influenza A was more frequent than B, with predominance of the A/H1N1/pdm09 subtype. The flu-like virus which infected most children was the human respiratory syncytial virus (RSV). The greatest number of cases with RSV was registered in the group of the youngest children (0-4 years). CONCLUSIONS This population study from Poland showed that during the COVID-19 pandemic, and during the winter influenza season of 2019/20, influenza and influenza-like viral infections in children showed some differences from previous influenza seasons. The findings highlight the importance of viral infection surveillance and influenza vaccination in the pediatric population.


Asunto(s)
COVID-19 , Gripe Humana/epidemiología , Academias e Institutos , Distribución por Edad , Niño , Preescolar , Humanos , Lactante , Gripe Humana/diagnóstico , Masculino , Pandemias , Polonia/epidemiología , Reacción en Cadena de la Polimerasa , SARS-CoV-2
6.
Adv Exp Med Biol ; 1324: 21-28, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-32946038

RESUMEN

Vaccination is the most effective preventive measure that reduces the risk of influenza and post-influenza complications. It prevents influenza-related hospitalizations and deaths in 50-60% and about 80% of patients aged over 65, respectively. There is the clinical plausibility of the association between serum vitamin D (VIT D) content and viral respiratory infections. In this study, we addressed the issue of a vitamin D modulatory effect on the immune response to seasonal influenza vaccination in elderly persons. The study comprised 96 participants aged 60-75 during the 2016/17 epidemic season. After the determination of the baseline content of VIT D and anti-hemagglutinin antibodies (H1, H3, and HB), participants were vaccinated with a trivalent vaccine. The content of the anti-hemagglutinin antibodies was rechecked 4-5 weeks afterward, showing inappreciable alterations. The negative findings of this study make the influence of serum VIT D content on the immunogenicity of influenza vaccination highly unlikely in elderly persons.


Asunto(s)
Vacunas contra la Influenza , Gripe Humana , Anciano , Anticuerpos Antivirales , Humanos , Gripe Humana/prevención & control , Persona de Mediana Edad , Estaciones del Año , Vacunación , Vitamina D
7.
Adv Exp Med Biol ; 1251: 115-121, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31989546

RESUMEN

The objective of this review was to elaborate on changes in the virological characteristics of influenza seasons in Poland in the past decade. The elaboration was based on the international influenza surveillance system consisting of Sentinel and non-Sentinel programs, recently adopted by Poland, in which professionals engaged in health care had reported tens of thousands of cases of acute upper airway infections. The reporting was followed by the provision of biological specimens collected from patients with suspected influenza and influenza-like infection, in which the causative contagion was then verified with molecular methods. The peak incidence of influenza infections has regularly been in January-March each epidemic season. The number of tested specimens ranged from 2066 to 8367 per season from 2008/2009 to 2017/2018. Type A virus predominated in nine out of the ten seasons and type B virus of the Yamagata lineage in the 2017/2018 season. Concerning the influenza-like infection, respiratory syncytial virus predominated in all the seasons. There was a sharp increase in the proportion of laboratory confirmations of influenza infection from season to season in relation to the number of specimens examined, from 3.2% to 42.4% over the decade. The number of confirmations, enabling a prompt commencement of antiviral treatment, related to the number of specimens collected from patients and on the virological situation in a given season. Yet influenza remains a health scourge, with a dismally low yearly vaccination rate, which recently reaches just about 3.5% of the general population in Poland.


Asunto(s)
Gripe Humana/epidemiología , Gripe Humana/virología , Estaciones del Año , Humanos , Virus de la Influenza B/aislamiento & purificación , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Polonia/epidemiología , Vacunación/estadística & datos numéricos
8.
Adv Exp Med Biol ; 1023: 93-100, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-28730379

RESUMEN

Influenza vaccination is the best measure available to prevent seasonal influenza infection. The majority of studies on vaccine effectiveness in the 2015/16 season conducted in the European I-MOVE+ Project, show that a match between the circulating influenza strains in the general public and those included in the vaccine for the Northern Hemisphere was low to moderate. As part of I-MOVE+, Poland has implemented a case control negative study design and molecular biology methods, such as real time RT-PCR, to assess the vaccine match and effectiveness. The research described herein consisted of two major influenza vaccine effectiveness investigations conducted in Poland in the 2015/16 season. The general practice part of the study included 228 cases consisting of 159 type A, 65 type B, and 4 coinfections (types A + B), and 312 negative control cases. The hospital study part included 26 cases consisting of 21 type A, 2 type B, and 3 coinfections, and 13 negative control cases. The data were collected from patients of all ages recruited by 46 volunteering doctors in 15 Poland's provinces and three hospitals, respectively. In both study parts, only were seven patients and 12 control subjects vaccinated. Low vaccine coverage, a major limitation of the Polish study, makes the calculation of vaccine effectiveness for the Polish population hardly applicable statistically. Despite the crudeness of data, they were included into the common European analysis. The overall vaccine effectiveness amounted to 21.0% (95% CI: 74-122). It was somehow better for type B virus: 53.9% (95% CI: 47-87) and type A virus: 23.6% (95% CI: 83-185). A larger sample size is needed to achieve a desired interpretation of results on influenza vaccine effectiveness in Poland.


Asunto(s)
Instituciones de Atención Ambulatoria , Hospitales , Vacunas contra la Influenza/inmunología , Gripe Humana/inmunología , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Virus de la Influenza A/inmunología , Virus de la Influenza B/inmunología , Gripe Humana/epidemiología , Gripe Humana/virología , Masculino , Persona de Mediana Edad , Nasofaringe/virología , Polonia/epidemiología , Resultado del Tratamiento , Adulto Joven
9.
Reumatologia ; 61(3): 149-151, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37522142
10.
Med Sci Monit ; 23: 4880-4884, 2017 Oct 12.
Artículo en Inglés | MEDLINE | ID: mdl-29021518

RESUMEN

The Spanish influenza pandemic in the years 1918-1920 was the largest and most tragic pandemic of infectious disease in human history. Deciphering the structure of the virus (including the determination of complete genome sequence) of this pandemic and the phylogenetic analysis and explanation of its virulence became possible thanks to molecular genetic analysis of the virus isolated from the fixed and frozen lung tissue of influenza victims who died in 1918 and were buried frozen in Alaska and Spitsbergen. Epidemiological data from the course of this pandemic in Poland have not been previously published. For analysis, we used source materials such as clinical studies and case reports of doctors fighting against the pandemic and registries of influenza cases in units of the Polish Army and military hospitals. Clinically, the pandemic of 1918 was characterized by the same symptoms and course as influenza in other years. Pathologically, the disease was similar to the other pandemic, in that the destruction was mostly limited to the respiratory tract. The "Spanish" influenza pandemic of 1918-1920 took place in Poland in 3 epidemic waves. The peaks of morbidity and mortality occurred in the capital, Warsaw, in December 1918 and in December 1919 to January 1920. It is estimated that throughout the pandemic period of 1918-1920 in Poland, 200 000 to 300 000 people died.


Asunto(s)
Influenza Pandémica, 1918-1919/historia , Gripe Humana/epidemiología , Bases de Datos Factuales , Brotes de Enfermedades , Historia del Siglo XX , Humanos , Subtipo H1N1 del Virus de la Influenza A , Influenza Pandémica, 1918-1919/mortalidad , Pandemias , Filogenia , Polonia/epidemiología
11.
Med Sci Monit ; 23: 1106-1115, 2017 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-28253223

RESUMEN

BACKGROUND The aim of this study was to assess the clinical course and distinctive features of different white dot syndromes (WDS) in patients attending the Ophthalmology Department, Medical University of Warsaw in the years 1995-2015. MATERIAL AND METHODS Sixty-two (62) patients (43 females and 19 males), aged 18 to 77 years, referred with a WDS were included in this prospective study, with observation period ranging from 5 months to 16 years. All patients underwent a complete ophthalmological examination and multimodal imaging studies. RESULTS In this cohort of 62 patients, the following WDS entities were identified: multifocal choroiditis with panuveitis (MFCPU), multifocal choroiditis (MFC), punctate inner choroidopathy (PIC), birdshot, acute posterior multifocal placoid pigment epitheliopathy (APMPPE), subretinal fibrosis and uveitis, multiple evanescent white dot syndrome (MEWDS), serpiginous choroiditis, and single cases of acute annular outer retinopathy (AAOR). CONCLUSIONS The study was performed at a Polish referral center and may to some extent reflect the varied geographical distribution of white dot syndromes, as none of the subjects was found to suffer from acute zonal occult outer retinopathy (AZOOR), acute macular neuroretinopathy (AMN), or diffuse unilateral subacute neuroretinitis (DUSN). Long-term follow-up is warranted by the evolution of lesions in the eye fundus, while management depends on correct diagnosis of WDS. When the posterior pole is involved in some cases of the WDS an immunosuppressive treatment, the use of the PDT or anti-VEGF injections were necessary.


Asunto(s)
Coroiditis/patología , Enfermedades de la Retina/diagnóstico , Agudeza Visual/fisiología , Adolescente , Adulto , Anciano , Coroiditis/diagnóstico , Oftalmopatías/diagnóstico , Femenino , Fondo de Ojo , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Coroiditis Multifocal , Panuveítis/patología , Fotograbar/métodos , Estudios Prospectivos
12.
Adv Exp Med Biol ; 968: 1-6, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28315128

RESUMEN

Influenza may have a complicated course in young children. The aim of the study was to analyze the suitability of influenza treatment among children younger than 5 years hospitalized due to an influenza-like illness. We conducted a comparison of the treatment among children hospitalized in two consecutive years: 2015, when no rapid influenza diagnostic tests (RIDT) were in use, and 2016, when RIDT were implemented into a routine practice in the pediatric ward. In both seasons, nasopharyngeal swabs were collected and examined with real time qRT-PCR. In the 2015 season, influenza was diagnosed in 15/52 (28 %) children and none of them received oseltamivir, while 14/15 (93 %) patients received antibiotics. In the 2016 season, influenza was diagnosed in 11/63 (17 %) children, 7/11 (64 %) of them received oseltamivir and another 7/11 (64 %) received antibiotics. In four cases antibiotics overlapped oseltamivir. These differences in the use of oseltamivir and antibiotics were statistically significant (p < 0.05). We conclude that the implementation of RIDT improves the suitability of influenza treatment and decreases the frequency of antibiotic therapy. RIDT should be available in pediatric departments to optimize influenza treatment.


Asunto(s)
Antivirales/administración & dosificación , Gripe Humana/diagnóstico , Oseltamivir/administración & dosificación , Niño Hospitalizado , Preescolar , Femenino , Humanos , Lactante , Virus de la Influenza A/efectos de los fármacos , Virus de la Influenza A/genética , Virus de la Influenza A/aislamiento & purificación , Virus de la Influenza A/fisiología , Gripe Humana/tratamiento farmacológico , Gripe Humana/virología , Masculino
13.
Adv Exp Med Biol ; 968: 19-34, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28315129

RESUMEN

Patients at a high-risk of severe influenza, because of their underlying health disorders, are recommended to receive a seasonal influenza vaccination. In Poland, influenza coverage rate in the general population is very low (3.4 %). However, there is little known about the coverage rate among high-risk patients. The aim of this study was to describe a general knowledge, perception, and influenza vaccination coverage rate among Polish patients with enhanced risk for influenza. We conducted a self-reported survey among 500 patients with chronic disorders: 120 pulmonary, 80 hemodialyzed, 100 thyroid cancer, and 200 cardiovascular patients. We found the following influenza vaccination coverage in the respective groups of patients: 58 % in pulmonary, 34 % in hemodialyzed, 32 % in cardiovascular, and 9 % in thyroid cancer patients. The difference between the coverage rate in pulmonary patients compared with the other risk groups was significant (p < 0.05). In pulmonary patients, the most important barrier for influenza vaccination was a lack of recommendations from healthcare workers, while a high awareness of influenza was the most powerful driver for vaccination (p < 0.05). We conclude that although the influenza vaccination coverage in Polish patients with chronic diseases is higher than that reported in the general population, this rate remains much below the recommended level and should be improved.


Asunto(s)
Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Orthomyxoviridae/inmunología , Adulto , Anciano , Enfermedad Crónica/epidemiología , Enfermedad Crónica/psicología , Estudios Transversales , Femenino , Humanos , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/inmunología , Gripe Humana/epidemiología , Gripe Humana/psicología , Gripe Humana/virología , Conocimiento , Masculino , Persona de Mediana Edad , Orthomyxoviridae/genética , Percepción , Polonia/epidemiología , Encuestas y Cuestionarios , Vacunación/psicología , Adulto Joven
14.
Postepy Hig Med Dosw (Online) ; 70: 313-8, 2016 Apr 18.
Artículo en Polaco | MEDLINE | ID: mdl-27117107

RESUMEN

Influenza surveillance was established in 1947. From this moment WHO (World Health Organization) has been coordinating international cooperation, with a goal of monitoring influenza virus activity, effective diagnostic of the circulating viruses and informing society about epidemics or pandemics, as well as about emergence of new subtypes of influenza virus type A. Influenza surveillance is an important task, because it enables people to prepare themselves for battle with the virus that is constantly mutating, what leads to circulation of new and often more virulent strains of influenza in human population. As vaccination is the most effective method of fighting the virus, one of the major tasks of GISRS is developing an optimal antigenic composition of the vaccine for the current epidemic season. European Influenza Surveillance Network (EISN) has also developed over the years. EISN is running integrated epidemiological and virological influenza surveillance, to provide appropriate data to public health experts in member countries, to enable them undertaking relevant activities based on the current information about influenza activity. In close cooperation with GISRS and EISN are National Influenza Centres--national institutions designated by the Ministry of Health in each country.


Asunto(s)
Vacunas contra la Influenza/administración & dosificación , Gripe Humana/epidemiología , Vigilancia de Guardia , Humanos , Vacunas contra la Influenza/inmunología , Orthomyxoviridae/inmunología , Pandemias
15.
Przegl Epidemiol ; 70(3): 407-419, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27883286

RESUMEN

OBJECTIVE: Analysis of epidemiological situation of influenza in Poland in 2013 and 2013/14 epidemic season in reference to previous years and seasons. MATERIAL AND METHODS: Analysis was based on: 1) data collected within influenza routine surveillance system in Poland, including data published in annual bulletins "Infectious diseases and poisonings in Poland" as well as unpublished data gathered in the Department of Epidemiology of the NIPH-NIH; 2) data collected within influenza system - Sentinel, and beyond this system, concerning results of virological tests carried out in 2013/14 epidemic season in the Department of Influenza Research, National Influenza Center in the NIPHNIH and/or laboratories of provincial sanitary and epidemiological stations which are gathered in the National Influenza Center. RESULTS: Compared to 2012, the number of influenza and influenza-like cases increased more than twofold in 2013 in Poland. A total of 3 164 405 cases were reported. Incidence was 8 218.7 per 100,000 population (33 733.2 in 0-4 age group). As many as 0.45% of patients were referred to hospitals. According to the data of the Central Statistical Office, 115 deaths due to influenza were notified. Based on the data of the sanitary inspection (incomplete data), the percentage of population vaccinated against influenza was 2.4% (7.7% of persons aged more than 64 years). A total of 2 780 945 cases were registered in 2013/14 epidemic season. Its peak was reported in March 2014. Incidence was 7 224.0 per 100,000 population (35 172.8 in 0-4 age group). Compared to 2012/13 epidemic season, it was lower by 8.0%. Incidence rates ranged from 29 339.6 in pomorskie voivodeship to 1 306.5 in lubuskie voivodeship. Nearly a half of all cases (48.7%) were registered in children and adolescents up to 15 years. As many as 0.34% of patients were referred to hospitals (0.87% of persons aged more than 64 years). From the data of the Central Statistical Office transpires that 8 deaths due to influenza were reported in epidemic season. Type A influenza subtype H3N2 predominated in all influenza cases. Human respiratory syncytial virus (RSV) was the dominant agent in other viral infections of respiratory tract. Antigenic analysis of influenza strains showed their affinity with vaccine strains of the vaccine recommended for this epidemic season. CONCLUSIONS: In spite of slow improvements, influenza and influenza-like surveillance system in Poland is still not homogeneous and stable enough. It hinders the assessment of current epidemiological situation. For instance, there are difficulties in determining what is the effect of modifications in the surveillance on the increase in the number of influenza and influenza-like cases observed in Poland in recent years. A low percentage of population vaccinated against influenza (with a decreasing trend beginning from 2005) suggests a necessity of revising the methods of promotion and organization of these vaccines used so far. One of the public health priorities should be to increase the percentage of vaccinated population up to the average level in EU countries.


Asunto(s)
Vacunas contra la Influenza/uso terapéutico , Gripe Humana/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Niño , Preescolar , Humanos , Incidencia , Lactante , Recién Nacido , Gripe Humana/prevención & control , Persona de Mediana Edad , Polonia/epidemiología , Sistema de Registros , Estaciones del Año , Adulto Joven
16.
Adv Exp Med Biol ; 836: 47-54, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25248348

RESUMEN

Influenza vaccination is recommended to patients from groups at risk and to healthy persons alike. It is not completely clear whether persons vaccinated every year benefit more from the vaccination in any given season in comparison with those who are vaccinated for the first time. The aim of the study was to analyze whether influenza vaccination in previous seasons influences the response to ongoing vaccination in the healthy population and in hemodialyzed patients. The outcome measure was the production of anti-hemagglutinin antibodies in 71 hemodialyzed patients (Group A) and 63 patients of primary healthcare clinic, without chronic renal failure (Group B). The patients of these two groups were subdivided into never vaccinated before and previously vaccinated against influenza. After the current vaccination, significantly lower levels of anti-A/H1N1/ antibodies were found in the hemodialyzed compared with non-hemodialyzed previously vaccinated, but not unvaccinated, patients. The hemodialyzed patients, previously unvaccinated, had at baseline significantly lower levels of anti-A/H3N2/ and anti-B antibodies than those who were previously vaccinated; the differences were no longer significant after the current vaccination. We conclude that although antiflu immunization in previous seasons leads to higher baseline antibody titers in hemodialysis compromised patients, which is less evident in non-hemodialyzed patients, it is of little influence on the immunoresponse to current influenza vaccination, in both hemodialyzed and non-hemodialyzed patients.


Asunto(s)
Inmunidad Activa , Inmunización Secundaria , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Fallo Renal Crónico , Diálisis Renal , Vacunación , Anciano , Anciano de 80 o más Años , Femenino , Voluntarios Sanos , Humanos , Inmunización Secundaria/estadística & datos numéricos , Vacunas contra la Influenza/inmunología , Gripe Humana/epidemiología , Gripe Humana/inmunología , Fallo Renal Crónico/epidemiología , Fallo Renal Crónico/inmunología , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Vacunación/estadística & datos numéricos
17.
Przegl Epidemiol ; 68(3): 455-63, 559-65, 2014.
Artículo en Inglés, Polaco | MEDLINE | ID: mdl-25391010

RESUMEN

UNLABELLED: This paper aimed at evaluating the epidemiological situation of influenza in Poland in 2011-2012 and in 2011/2012 and 2012/2013 epidemic seasons and comparing it with the situation observed in the previous years. MATERIAL AND METHODS: An analysis was mainly based on three sources of data: (1) bulletins "Infectious diseases and poisonings in Poland in 2012" and "Vaccinations in Poland in 2012" (NIPH-NIH, CSI. Warsaw 2013) and analogically former bulletins, (2) "Reports on influenza cases and persons suspected of influenza", sent in 2013 and previous years to the Department of Epidemiology, NIPH-NIH by the Voivodeship Sanitary- Epidemiological Stations, (3) data of the Department of Influenza Research, National Influenza Centre, NIPH- NIH - results of virological testing performed in 2011/2012 and 2012/2013 epidemic seasons in the National Influenza Centre and/or laboratories of the Voivodeship Sanitary-Epidemiological Stations (VSES) within influenza surveillance - Sentinel as well as beyond this system. Data on influenza cases come from aggregated notifications which are sent obligatorily to the VSES by all health care units and physician practices. Influenza, influenza-like illness and acute respiratory infections, i.e. cases meeting the criteria recommended in influenza surveillance in the European Union are subject to mandatory notification. RESULTS: In 2011-2012, there was an increase in the number of influenza and influenza-like illness cases in Poland compared to 2010, i.e. 2- and 2,5-fold, respectively. In 2011, a total of 1 156 357 cases were reported and incidence amounted to 3 001.5 per 100,000 population (11 014.5 in age group 0-4 years). As many as 0.51% of infected persons were referred to hospital. According to the CSO data, 95 fatal cases of influenza were notified. Influenza vaccination coverage was 2.8%. In 2012, 1 460 037 cases were registered and incidence was 3 789.0 (17 807,1 in age group 0-4 years). A total of 0.33% of influenza cases were referred to hospital. As many as 4 deaths due to influenza were reported. Percentage of population vaccinated against influenza amounted to 2.3%. In 2011/12 epidemic season, 1 085 471 cases were noted and incidence was 2 816.6 per 100,000 population (12 792.3 in age group 0-4 years) while in 2012/13 epidemic season its number was nearly 3-fold higher, i.e. 3 025 258 cases and incidence - 7 851.0 (30 591.7 in age group 0-4 years). In both epidemic seasons, type A influenza subtype H1N1 and human respiratory syncytial virus (RSV) predominated in infections with influenza virus and other viral respiratory infections, respectively. Antigenic analysis of influenza strains showed their affinity with vaccine strains of the vaccines recommended for these epidemic seasons. SUMMARY: An increase in the number of notified cases of influenza and influenza-like illness, which is recently observed in Poland, is significantly affected by the improving quality (especially sensitivity) of surveillance system, commenced in the 2009 influenza pandemic. This surveillance system, however, is still not sufficiently uniform and stable. Low percentage of population vaccinated against influenza suggests the ineffectiveness of influenza vaccine promotion campaigns conducted so far. An increase in the influenza vaccination coverage to the average observed in the EU countries should be one of the priorities for the sanitary-epidemiological stations.


Asunto(s)
Epidemias/estadística & datos numéricos , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/epidemiología , Gripe Humana/virología , Sistema de Registros , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Epidemias/prevención & control , Femenino , Humanos , Lactante , Recién Nacido , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Virus de la Influenza B/aislamiento & purificación , Gripe Humana/prevención & control , Masculino , Persona de Mediana Edad , Polonia/epidemiología , Virus Sincitiales Respiratorios/aislamiento & purificación , Población Rural/estadística & datos numéricos , Población Urbana/estadística & datos numéricos , Adulto Joven
18.
Acta Biochim Pol ; 71: 12289, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38721309

RESUMEN

The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0-4 years of age, 5-9 years of age, 10-14 years of age, 15-25 years of age, 26-44 years of age, 45-64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection.


Asunto(s)
Anticuerpos Antivirales , Glicoproteínas Hemaglutininas del Virus de la Influenza , Subtipo H1N1 del Virus de la Influenza A , Subtipo H3N2 del Virus de la Influenza A , Gripe Humana , Humanos , Polonia/epidemiología , Adulto , Persona de Mediana Edad , Adolescente , Gripe Humana/inmunología , Gripe Humana/epidemiología , Gripe Humana/sangre , Gripe Humana/virología , Niño , Anciano , Preescolar , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Adulto Joven , Lactante , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Masculino , Subtipo H1N1 del Virus de la Influenza A/inmunología , Subtipo H3N2 del Virus de la Influenza A/inmunología , Femenino , Recién Nacido , Pruebas de Inhibición de Hemaglutinación , Virus de la Influenza B/inmunología , Estaciones del Año , Epidemias , Prevalencia
19.
Arch Virol ; 158(8): 1743-53, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23515874

RESUMEN

This study was performed to develop real-time PCR (qPCR) for detection of human seasonal and avian influenza viruses in duplex format. First duplex qPCR detects haemagglutinin (HA) gene of influenza virus A(H1N1)pdm09 and HA gene of influenza virus A(H3N2), the second reaction detects neuraminidase (NA) gene of influenza virus A(H3N2) and NA gene of influenza virus A(H1N1)pdm09 and A(H5N1), and the third reaction detects HA gene of influenza A(H5N1) and nonstructural protein gene of influenza B virus. Primers and probes were designed using multiple alignments of target gene sequences of different reference strains. Assays were optimised for identical thermocycling conditions. Their specificity was confirmed by conventional PCR and monoplex qPCR with nucleic acids isolated from different influenza viruses and other respiratory pathogens. Plasmid constructs with a fragment of specific gene were used to assess sensitivity of the assay. The limit of detection ranged from 27 to 96 cDNA copies/reaction. Clinical specimens (n = 107) have been tested using new assays, immunofluorescence and monoplex qRT-PCR. It has been shown that developed assays have been capable of rapid and accurate simultaneous detection and differentiation of influenza viruses. They are more sensitive than immunofluorescence and at least as sensitive as monoplex qRT-PCR.


Asunto(s)
Virus de la Influenza A/clasificación , Virus de la Influenza A/aislamiento & purificación , Gripe Humana/diagnóstico , Gripe Humana/virología , Reacción en Cadena de la Polimerasa Multiplex/métodos , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Virología/métodos , Cartilla de ADN/genética , Humanos , Virus de la Influenza A/genética , Técnicas de Diagnóstico Molecular/métodos , Sondas de Oligonucleótidos/genética , Sensibilidad y Especificidad
20.
Med Sci Monit ; 19: 1013-8, 2013 Nov 18.
Artículo en Inglés | MEDLINE | ID: mdl-24241247

RESUMEN

The influenza virus is one of the most common causes of viral respiratory tract infections. Some chronic diseases predispose to a severe course of the disease and increase the risk of complications and death. To minimize the risk of infection and complications, care of patients with increased risk should include prophylactic measures such as the administration of a seasonal influenza vaccine. An influenza vaccine is the best and cheapest method of influenza prevention. It is indicated for patients with chronic kidney disease, both during conservative treatment and renal replacement therapy. Many studies that have assessed the efficacy of an influenza vaccine in patients on hemodialysis have found that immune deficiency predisposes these patients to infection and a severe course of the disease. Because the immune response to a standard influenza vaccine in this population is weak, the studies covered many aspects of vaccination, including the need for a booster dose. Unlike in a healthy population, the efficacy of an influenza vaccine in patients on hemodialysis might be insufficient; however, the vaccine is still able to induce immunity in a significant number of patients. Considering the latest data and the results of studies described above, the recommendation of a seasonal influenza vaccine should be obligatory in all hemodialysis patients. This paper is based on original articles available from Medline database. The most recent and most significant literature on the influenza vaccine in patients on hemodialysis has been reviewed.


Asunto(s)
Vacunas contra la Influenza/uso terapéutico , Gripe Humana/prevención & control , Diálisis Renal , Insuficiencia Renal Crónica/terapia , Humanos , Gripe Humana/complicaciones , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/inmunología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA